Skip to content
Heart icon (animated) heart icon (static)
Explore more Johnson & Johnson sites:
A graphic of the flag of Australia alt
A graphic of the flag of Argentina alt
A graphic of the flag of Brazil alt
A graphic of the national flag of Canada alt
A graphic of the flag of Chile alt
A graphic of the national flag of the People's Republic of China alt
A graphic of the national flag of Colombia alt
A graphic of the national flag of Ecuador alt
A graphic of the flag of Germany alt
A graphic of the national flag of India alt
A graphic of the national flag of Japan alt
A graphic of the flag of Mexico alt
A graphic of the flag of Paraguay alt
A graphic of the flag of Peru alt
A graphic of the flag of Russia alt
Switzerland
A graphic of the flag of Switzerland alt
A graphic of the national flag of Uruguay alt
A graphic of the flag of Venezuela alt
Share
Download Report
= Achieved

Pharmaceutical Pipeline – Key Events in 2021*

POTENTIAL APPROVALS US/EU

CABENUVA (rilpivrine long acting)

HIV
US

ciltacabtagene autoleucel (BCMA CAR-T)

Relapsed refractory Multiple Myeloma
US

DARZALEX (daratumumab)

Amyloidosis (ANDROMEDA)
US
EU

DARZALEX (daratumumab)

Relapsed Refractory Multiple Myeloma w/PomDex
US
EU

INVEGA HAFYERA (PP6M)

Schizophrenia
US

PONVORY (ponesimod)

Relapsing forms of multiple sclerosis
US
EU

RYBREVANT (amivantamab)

Non Small Cell Lung Cancer
US

SPRAVATO (esketamine nasal spray)

Major Depressive Disorder in a Psychiatric Emergency
EU

UPTRAVI IV (selexipag)

Pulmonary arterial hypertension
US

VAC31518

Janssen COVID-19 Vaccine
EUA US
cMAA EU

XARELTO (rivaroxaban)

Infrainguinal revascular PAD
US

XARELTO (rivaroxaban)

Pediatric VTE/CHD (Fontan)
US

PLANNED SUBMISSIONS US/EU

ciltacabtagene autoleucel (BCMA CAR-T)

Relapsed refractory Multiple Myeloma
Submission Complete US
EU

IMBRUVICA (ibrutinib)

Frontline Chronic Lymphocytic Leukemia (I + V fixed duration) (GLOW)
US
EU

RYBREVANT (amivantamab)

Non Small Cell Lung Cancer
EU

VAC31518

Janssen COVID-19 Vaccine
EUA US
cMAA EU

XARELTO (rivaroxaban)

Pediatric VTE/CHD (Fontan)
US

POTENTIAL CLINICAL DATA PRESENTATIONS

Phase II

ciltacabtagene autoleucel (BCMA CAR-T)

Multiple Myeloma (CARTITUDE-1 Longer term follow-up)

milvexian (factor Xla)

Total Knee Replacement (AXIOMATIC-TKR)

RYBREVANT (amivantamab)

2L NSCLC (CHRYSALIS)

teclistamab (BCMA/CD3)

Relapsed refractory multiple myeloma (TECLIMMY1001)

VAC18193

RSV Adult Vaccine (CYPRESS)
Phase III

DARZALEX (daratumumab)

Multiple Myeloma (MAIA) Overall Survival Benefit

ERLEADA (apalutamide)

Metastatic castrate sensitive prostate cancer- Final Analysis (TITAN)

IMBRUVICA (ibrutinib)

Frontline chronic lymphocytic leukemia (I+V fixed duration) (GLOW)

INVEGA HAFYERA (PP6M)

Schizophrenia (ROUTE 6)

STELARA (ustekinumab)

Crohn’s Disease H2H vs. HUMIRA (SEAVUE)
*This information is accurate as of October 19, 2021 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.
This site uses cookies as described in our Cookie Policy Please click the "Accept" button or continue to use our site if you agree to our use of cookies.
Close cookie banner icon
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue